Development And Assessment Of A Bcs Class II - SGLT2 (Sodium Glucose Cotransporter 2) Inhibitor Drug In The Form Of Solid Lipid Nanoparticles By Selecting Different Lipids, Co-Surfactants, And Manufacturing Techniques

Solid lipid nanoparticles (SLNs) represent a promising drug delivery system capable of delivering a wide variety of drugs, including both hydrophobic and hydrophilic compounds. They can be customized for specific therapeutic applications, such as targeted drug delivery, sustained release, and reduced toxicity. The research focused on developing SLN formulations using emulsification-solvent evaporation and hot homogenization. This involved optimizing the concentrations of surfactants and co-surfactants/stabilizers to achieve stable formulations. Preliminary results indicated that the lipids and surfactants with the highest miscibility with the active pharmaceutical ingredient (API) were selected. The lipid, surfactant, and co-surfactant concentrations were optimized to create a stable formulation. The study found that the API exhibited poor thermal stability up to the melting points of the shortlisted excipients, retained its BCS (Biopharmaceutical Classification System) class II classification, and showed low solubility and permeability. However, the selected API was determined to have a dose of approximately 2.5 mg, demonstrating improved thermal stability and degradation behavior. The minimum concentrations of lipids required to achieve a stable formulation were also established. With appropriate formulation and process optimization, SLNs are promising for future therapeutic applications, particularly in chemotherapy, vaccine delivery, and gene therapy.